StemCell Therapy

Want FREE access to this Audio Article?

Complete the form below to unlock access to this Audio Article: "What are Progenitor Cells? Exploring Neural, Myeloid and Hematopoietic Progenitor Cells"

Every cell in the human body, and that of other mammals, originates from stem cell precursors. Progenitor cells are descendants of stem cells that then further differentiate to create specialized cell types.There are many types of progenitor cells throughout the human body. Each progenitor cell is only capable of differentiating into cells that belong to the same tissue or organ. Some progenitor cells have one final target cell that they differentiate to, while others have the potential to terminate in more than one cell type.

Stem cells share two qualifying characteristics. Firstly, all stem cells have the potential to differentiate into multiple types of cells. Secondly, stem cells are capable of unlimited self-replication via asymmetric cell division, a process known as self-renewal.There are two broad categories of stem cells found in all mammals. The first are embryonic stem cells. These cells arise from the inner cell mass of the blastocyst in an early-stage embryo. Embryonic stem cells are the blueprint used to create every cell in the body. Because they can be used to create any type of cell, they are known as pluripotent.

The second type of stem cells found in mammals are adult stem cells (or somatic stem cells). Unlike pluripotent embryonic stem cells, adult stem cells are more limited in relation to the type of cells that they become. Unlike embryonic stem cells that could be used to create any cell, adult stem cells are limited to generating cell types within a specific lineage, such as blood cells or cells of the central nervous system. This level of differentiation potential is termed multipotent.

Stem cells create two types of progeny: more stem cells or progenitor cells. All progenitor cells are descendants of stem cells. When it comes to cell differentiation, they fall on the spectrum between stem cells and fully differentiated (mature) cells.

Whilst stem cells have indefinite replication (left) progenitor cells can at most differentiate into multiple types of specialized cell (right).

Function:

Cellular repair or maintenance

Cell Potency:

Multipotent, oligopotent, or unipotent

Self-renewal:

Limited

Origin:

Stem cells

Creates:

Further differentiated cells (either progenitor cells of mature/fully differentiated cells)

Progenitor cells are an intermediary step involved in the creation of mature cells in human tissues and organs, the blood, and the central nervous system.

The human central nervous system (CNS) contains three types of fully differentiated cells: neurons, astrocytes and oligodendrocytes. The latter two are collectively known as glial cells.Every neuron, oligodendrocyte and astrocyte in the CNS evolves from the differentiation of neural progenitor cells (NPCs). NPCs themselves are produced by multipotent neural stem cells (NSCs). Both NPCs and NSCs are termed neural precursor cells.Before the 1990s, it was believed that neurogenesis terminated early in life. More recent studies demonstrate that the brain contains stem cells that are capable of regenerating neurons and glial cells throughout the human lifecycle. These stem cells have only been found in certain brain regions, including the striatum and lateral ventricle.

Hematopoietic progenitor cells (HPCs) are an intermediate cell type in blood cell development. HPCs are immature cells that develop from hematopoietic stem cells, cells that can both self-renew and differentiate into hematopoietic progenitor cells. HPCs eventually differentiate into one of more than ten different types of mature blood cells.Hematopoietic progenitor cells are categorized based upon their cell potency, or their differentiation potential. As blood cells develop, their potency decreases.

First, hematopoietic stem cells differentiate into multipotent progenitor cells. Multipotent progenitor cells are those with the potential to differentiate into a subset of cell types. These cells then differentiate into either the common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). Both CMPs and CLPs are types of oligopotent progenitor cells (progenitor cells that differentiate into only a few cell types).

CMPs and CLPs continue to differentiate along cell lines into lineage-restricted progenitor cells that become final, mature blood cells.Myeloid progenitor cells are precursors to the following types of blood cells:

Lymphoid progenitor cells (also known as lymphoblasts) are precursors to other mature blood cell types, including:

The primary role of progenitor cells is to replace dead or damaged cells. In this way, progenitor cells are necessary for repair after injury and as part of ongoing tissue maintenance. Progenitor cells also replenish blood cells and play a role in embryonic development.

Neural progenitor cells (NPCs) are being explored alongside neural stem cells for their potential to treat diseases of or injury to the central nervous system. A deeper understanding of how these cells function on a cellular and molecular basis is needed to progress from early experimental research to therapeutic use.NPCs are currently utilized in research conducted on CNS disorders, development, cell regeneration and degeneration, neuronal excitability, and therapy screening. When compared to induced pluripotent stem cells, which are cells reprogrammed into a pluripotent state, NPCs can cut down on time in some experiments.Hematopoietic progenitor cells and stem cells are being researched for their capacity to treat blood cell disorders. They are also currently used to help treat patients with a variety of malignant and non-malignant diseases via bone marrow transplants that deliver bone marrow and peripheral blood progenitor cells to patients. These procedures can assist patients in recovering from the damage caused by chemotherapy.Additionally, researchers are examining the potential of using progenitor cells to create a variety of tissues, such as blood vessels, heart valves, and electrically conductive tissue for the cardiovascular system.

Read this article:
What are Progenitor Cells? Exploring Neural ... - Technology Networks

DUBLIN--(BUSINESS WIRE)--The "Biotechnology Market Research Report by Technology (Cell-based Assays, Chromatography, and DNA Sequencing), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Biotechnology Market size was estimated at USD 876.74 billion in 2021, USD 1,023.15 billion in 2022, and is projected to grow at a CAGR 16.87% to reach USD 2,234.84 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biotechnology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biotechnology Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biotechnology Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biotechnology Market?

4. What is the competitive strategic window for opportunities in the Global Biotechnology Market?

5. What are the technology trends and regulatory frameworks in the Global Biotechnology Market?

6. What is the market share of the leading vendors in the Global Biotechnology Market?

7. What modes and strategic moves are considered suitable for entering the Global Biotechnology Market?

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ijpdlj

Read the rest here:
The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 - ResearchAndMarkets.com - Business Wire

In brief

By National Law No. 27,685 ("Law"), published on 16 September 2022, Law No. 26,270 was amended, expanding throughout the entire national territory the promotion regime for the development and production of modern biotechnology and nanotechnology. The regime will be in force up to 31 December 2034.

The Law set forth the following tax benefits: (i) the accelerated amortization of the capital goods, special equipment, and parts or elements forming those new goods, which were acquired for the project; (ii) the anticipated refund for the VAT corresponding to the goods acquired for the project; and (iii) the granting of a tax credit bond equivalent to 50% of expenses paid for hiring investigative and development services from institutions that are part of the national public system of science, technology and innovation. The tax credit bond will be valid for 10 years and it will only be transferable once.

In focus

The Law includes the concept of nanotechnology in the definition of "Modern Biotechnology", which means every technological application based on rational knowledge and scientific principles that derive from biology, biochemistry, microbiology, bioinformatics, molecular biology and genetic engineering, or that uses live organisms or parts of them, either for the production of goods and services, or for the substantial improvement of products and productive processes.

The Law set forth the following tax benefits:

Click here to download the Spanish version.

Content is provided for educational and informational purposes only and is not intended and should not be construed as legal advice. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee similar outcomes. For more information, please visit:www.bakermckenzie.com/en/client-resource-disclaimer.

Read more from the original source:
Argentina: Promotion of modern biotechnology and nanotechnology - Lexology

Press release

Cambridge, MA U.S.A. (September 26, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022.

Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director.

I am delighted that Jerry has chosen to join Allaritys board at this crucial time in our evolution, said Dr. Duncan Moore, Allaritys Chairman of the Board. His operational experience in clinical stage therapeutic development and capital markets acumen will be of great value as we continue to implement the Companys combination therapy-focused strategy.

Mr. McLaughlin said: I firmly believe Allarity Therapeutics is in a unique position to become a leader within the personalized medicine space by developing novel combination oncology therapies together with the Companys unique DRP companion diagnostics. Allaritys recent strategic shift is aligned with the ongoing patient and market realities in oncology, as we continue to see substantially higher patient benefits with combination therapies. I look forward to supporting the CEO, Jim Cullem, and the rest of the Allarity team in unlocking both the clinical and commercial potential of this strategy.

Mr. McLaughlin has three decades of experience in leading operational and executive management roles. He made key contributions to significant life science milestones, including product launches, acquisitions, and financings. He is currently serving as CEO and Board Member of Life Biosciences, LLC, a development-stage biopharmaceutical company advancing therapeutics for patients with neurological and psychiatric diseases. Prior to serving in this role, he was President, CEO, and Member of the Board of Directors at Neos Therapeutics (acquired by Aytu BioScience.) Before joining Neos Therapeutics, he served as President, CEO, and Member of the Board of Directors at AgeneBio, Inc. Earlier in his career, he held corporate leadership roles at NuPathe, Inc., Endo Pharmaceuticals Inc., and Merck & Co., Inc. He received his B.A. from Dickinson College and his MBA from Villanova University in Pennsylvania.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; and the European rights to IXEMPRA (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis, a liposomal formulation of cisplatin and its accompanying DRP, being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Companys website at http://www.Allarity.com.

About the Drug Response Predictor DRP Companion Diagnostic

Allarity uses its drug-specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP score, the therapeutic response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA. The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.

Follow Allarity on Social Media

Facebook: https://www.facebook.com/AllarityTx/ LinkedIn: https://www.linkedin.com/company/allaritytx/ Twitter: https://twitter.com/allaritytx

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allaritys current expectations or forecasts of future events. The words anticipates, believe, continue, could, estimate, expect, intends, may, might, plan, possible, potential, predicts, project, should, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to clinical and commercial potential due to the Company advancing dovitinib in combination with another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Companys DRP companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to,the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Companys current and future clinical trials and the timing of the Companys preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our Form S-1 registration statementon file with theSecurities and Exchange Commission, available at the Securities and Exchange Commissions website atwww.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Companys subsequent filings with theSecurities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact:

Thomas JensenSenior V.P. of Investor Relationsinvestorrelations@allarity.com

Investor Relations:

Chuck PadalaLifeSci Advisors+1(646) 627-8390chuck@lifesciadvisors.comU.S. Media Contact:

Mike Beyer Sam Brown, Inc. +1 (312) 961-2502 mikebeyer@sambrown.com

EU Media Contact:

Thomas PedersenCarrotize PR & Communications +45 6062 9390tsp@carrotize.com

Read the original post:
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors - GlobeNewswire

As a rapidly advancing climate emergency turns the planet ever hotter, the Dallas-based biotechnology company Colossal Biosciences has a vision: To see the Woolly Mammoth thunder upon the tundra once again. Founders George Church and Ben Lamm have already racked up an impressive list of high-profile funders and investors, including Peter Thiel, Tony Robbins, Paris Hilton, Winklevoss Capital and, according to the public portfolio its venture capital arm released this month, the CIA.

Colossal says it hopes to use advanced genetic sequencing to resurrect two extinct mammals not just the giant, ice age mammoth, but also a mid-sized marsupial known as the thylacine, or Tasmanian tiger, that died out less than a century ago. On its website, the company vows: Combining the science of genetics with the business of discovery, we endeavor to jumpstart natures ancestral heartbeat.

In-Q-Tel, its new investor, is registered as a nonprofit venture capital firm funded by the CIA. On its surface, the group funds technology startups with the potential to safeguard national security. In addition to its long-standing pursuit of intelligence and weapons technologies, the CIA outfit has lately displayed an increased interest in biotechnology and particularly DNA sequencing.

Why the interest in a company like Colossal, which was founded with a mission to de-extinct the wooly mammoth and other species? reads an In-Q-Tel blog post published on September 22. Strategically, its less about the mammoths and more about the capability.

Biotechnology and the broader bioeconomy are critical for humanity to further develop. It is important for all facets of our government to develop them and have an understanding of what is possible, Colossal co-founder Ben Lammwrote in an email to The Intercept. (A spokesperson for Lamm stressed that while Thiel provided Church with$100,000 in funding to launchthe woolly mammoth project that became Colossal, he is not a stakeholderlike Robbins, Hilton, Winklevoss Capital, and In-Q-Tel.)

Colossal uses CRISPR gene editing, a method of genetic engineering based on a naturally occurring type of DNA sequence. CRISPR sequences present on their own in some bacterial cells and act as an immune defense system, allowing the cellto detect and excise viral material thattries to invade. The eponymous gene editing technique was developed to function the same way, allowing users to snip unwanted genes and program a more ideal version of the genetic code.

CRISPR is the use of genetic scissors, Robert Klitzman, a bioethicist at Columbia University and a prominent voice of caution on genetic engineering, told The Intercept. Youre going into DNA, which is a 3-billion-molecule-long chain, and clipping some of it out and replacing it. You can clip out bad mutations and put in good genes, but these editing scissors can also take out too much.

The embrace of this technology, according to In-Q-Tels blog post, will help allow U.S. government agencies to read, write, and edit genetic material, and, importantly, tosteerglobal biological phenomena that impact nation-to-nation competition whileenabling the United States to help set the ethical, as well as the technological, standards for its use.

In-Q-Tel did not respond to The Intercepts requests for comment.

In recent years, the venture firms portfolio has expanded to include Ginkgo Bioworks, a bioengineering startup focused on manufacturing bacteria for biofuel and other industrial uses; Claremont BioSolutions, a firm that produces DNA sequencing hardware; Biomatrica and T2 Biosystems, two manufacturers for DNA testing components; and Metabiota, an infectious disease mapping and risk analysis database powered by artificial intelligence. As The Intercept reported in 2016, In-Q-Tel also invested in Clearista, a skincare brand that removes a thin outer epidermal layer to reveal a fresher face beneath it and allow DNA collection from the skin cells scraped off.

President Joe Bidens administration signaled its prioritization of related advances earlier this month, when Biden signed an executive order on biotechnology and biomanufacturing. The order includes directives to spur public-private collaboration, bolster biological risk management, expand bioenergy-based products, and engage the international community to enhance biotechnology R&D cooperation in a way that is consistent with United States principles and values.

The governments penchant for controversial biotechnology long predates the Biden administration. In 2001, a New York Times investigation found that American defense agencies under Presidents George W. Bush and Bill Clinton had continued to experiment with biological weapons, despite a 1972 international treaty prohibiting them. In 2011, The Guardian revealed that the CIA under President Barack Obama organized a fake Hepatitis B vaccine drive in Pakistan that sought to locate family members of Osama bin Laden through nonconsensual DNA collection, leading the agency to eventually promise a cessation of falseimmunization campaigns.

CIA Labs, a 2020 initiative overseen by Donald Trumps CIA director, Gina Haspel infamous for running a torture laboratory in Thailand follows a model similar to In-Q-Tels. The program created a research network to incubate top talent and technology for use across U.S. defense agencies, while simultaneously allowing participating CIA officers to personally profit off their research and patents.

In-Q-Tel board members are allowed to sit on the boards of companies in which the firm invests, raising ethics concerns over howthe non-profit selects companies to back with government dollars. A 2016 Wall Street Journal investigation found that almost half of In-Q-Tel board members were connected to the companies where it had invested.

The size of In-Q-Tels stake in Colossal wont be known until the nonprofit releases its financial statements next year, but the investment may provide a boon on reputation alone: In-Q-Tel has claimed that every dollar it invests in a business attracts 15 more from other investors.

Colossals co-founders, Lamm and Church, represent the ventures business and science minds, respectively. Lamm, a self-proclaimed serial technology entrepreneur, founded his first company as a senior in college, then pivoted to mobile apps and artificial intelligence before helping to start Colossal.

Church a Harvard geneticist, genome-based dating app visionary, and former Jeffrey Epstein funding recipient has proposed the revival of extinct species before. Speaking to Der Spiegel in 2013, Church suggested the resurrection of the Neanderthal an idea met with controversy because it would require technology capable of human cloning.

We can clone all kinds of mammals, so its very likely that we could clone a human, Church said. Why shouldnt we be able to do so? When the interviewer reminded him of a ban on human cloning, Church said, And laws can change, by the way.

Even when the methods used for de-extinction are legal, many scientists are skeptical of its promise. In a 2017 paper for Nature Ecology & Evolution, a group of biologists from Canada, Australia, and New Zealand found that [s]pending limited resources on de-extinction could lead to net biodiversity loss.

De-extinction is a fairytale science, Jeremy Austin, a University of Adelaide professor and director of the Australian Center for Ancient DNA,toldthe Sydney Morning Herald over the summer, when Colossal pledged to sink $10 million into the University of Melbourne for its Tasmanian tiger project. Its pretty clear to people like me that thylacine or mammoth de-extinction is more about media attention for the scientists and less about doing serious science.

Critics who say de-extinction of genes to create proxy species is impossible are critics who are simply not fully informed and do not know the science. We have been clear from day one that on the path to de-extinction we will be developing technologies which we hope to be beneficial to both human healthcare as well as conservation, Lamm wrote to The Intercept. We will conitnue [sic] to share these technologies we develop with the world.

It remains to be seen if Colossal, with In-Q-Tels backing, can make good on its promises. And its unclear what, exactly, the intelligence world might gain from the use of CRISPR. But perhaps the CIA shares the companys altruistic, if vague, motives: To advance the economies of biology and healing through genetics. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet, can breathe easier.

Update: September 28, 2022, 1:00 p.m. ETThis story has been updated with a statement from Colossal co-founder Ben Lamm.

View post:
CIA Just Invested In Woolly Mammoth Resurrection Tech - The Intercept

Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis

Novel combination strategy designed toreduce HDV viremia and block viral entry

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that diminishes the level of all HBV proteins in vitro, including hepatitis B surface antigen, a protein necessary to create infectious HDV virions. VIR-3434 is an investigational hepatitis B surface antigen targeting monoclonal antibody designed to remove both HBV and HDV virions from the blood and block the entry of these viruses into liver cells. VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial. Previously reported results from Part A of the MARCH trial demonstrated that the combination of VIR-3434 and VIR-2218 resulted in an approximate 3 log decline in hepatitis B surface antigen (HBsAg).

Globally, more than 12 million people are living with HDV, and with no approved therapies available in the United States, there is an urgent need for the development of novel treatment strategies that will improve outcomes for patients, said Carey Hwang, M.D., Ph.D., Virs senior vice president, clinical research, head of chronic infection. Recent research suggests that reducing HDV viremia, by preventing virion formation as well as facilitating virion removal, in conjunction with blocking HDV virion entry into liver cells could be effective in suppressing chronic HDV infection. The initiation of SOLSTICE, our first clinical trial in HDV, is an important milestone as we advance our broad therapeutic portfolio for viral hepatitis, which also includes the pursuit of a functional cure for chronic HBV infection.

Design of the Phase 2 SOLSTICE TrialThe multi-center, open-label Phase 2 SOLSTICE trial is designed to evaluate the safety, tolerability, and efficacy of VIR-2218 and VIR-3434 in adult patients (age 18 to 69) with chronic HDV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Depending on the cohort, trial participants will receive multiple doses of VIR-2218 and VIR-3434 as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks. The primary endpoints of the trial are the proportion of study participants achieving either a 2log10 decrease in HDV RNA compared to baseline, or HDV RNA less than the limit of quantification and normalization of alanine transaminase (ALT) at Week 24, as well as the proportion of participants with treatment-emergent adverse events and serious adverse events. Vir expects initial data from the SOLSTICE trial in 2023.

About Chronic Hepatitis DChronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV). An estimated 12 million patients globally are infected with HDV, representing approximately 5% of those infected with HBV. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression toward hepatocellular carcinoma and liver-related death.

About Chronic Hepatitis BChronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality. Approximately 300 million people around the world are living with HBV and approximately 900,000 of them die from associated complications each year. These patients are significantly underserved by existing therapies with low functional cure rates, lifelong daily therapy and poor tolerability. Vir is working to achieve a functional cure for the millions of people with HBV around the world through its broad and differentiated portfolio.

About VIR-2218VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the Companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About VIR-3434VIR-3434 is an investigational subcutaneously administered antibody designed to block entry of HBV and HDV viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencors Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV and HDV in infected patients, as well as to have an extended half-life.

About Vir BiotechnologyVir Biotechnologyis a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, expect, anticipate, promising and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of VIR-2218 and VIR-3434 in combination to treat chronic HDV and HBV infection; the potential benefits of VIR-2218 and VIR-3434; Virs plans and expectations for its HDV and HBV portfolios; the initial results of the MARCH trial; the timing for and design of the Phase 2 SOLSTICE trial; the treatment of HDV and HBV; and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including risks that Vir may not fully enroll the Phase 2 SOLSTICE trial or it will take longer than expected; unexpected safety or efficacy data or results observed during the Phase 2 SOLSTICE trial or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; successful development and/or commercialization of alternative product candidates by Virs competitors; changes in expected or existing competition; delays in or disruptions to Virs business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Go here to see the original:
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis...

England is in crisis. They lost a beloved figurehead this month but for decades prior were losing scientific ground. If you look for the home of the modern organic food and anti-vaccine movements, you find their nexus in 1990s England.

The primary royal behind those beliefs is now King Charles III.

In order to manage the $28 billion he inherits (tax-free, paying taxes only applies to peasants in England)(1) he will have to give his $1.5 billion estate to his son, the new Prince of Wales, William (also tax free) but the Prince is not only taking over during a time when Brits are wondering why they still care about a throne that hasnt been relevant in hundreds of years, he is taking over at a time when being anti-science is no longer fashionable for progressive elites.

Though it was recently the darling of the intelligentsia, and Prince Charles longed to belong in that circle, anti-vaccine sentiments have become proletariat since COVID-19. The war on science when it comes to food harms a lot more people worldwide each year than the pandemic did. Hundreds of thousands of kids could stop going blind each year with Golden Rice but elites like King Charles III give money to groups that block its implementation.

Prince William could start to gain back some credibility for the family by jettisoning the organic food fetish of his father. Organic food, like the anti-vaccine movement, is a relic of 1990s England. Dr. Andrew Wakefield set off the modern anti-vaccine craze the same way that English environmental activists set off the Frankenfood one. Now supplements, wellness, and organic are all giant businesses based on exploitation of famous names who wanted to impress their elite friends

The world should have passed the anti-vaccine and anti-food movement by but they persist in large part because of the new British monarch and his quasi-American royalty of American Democrats counterpart, Robert F. Kennedy, Jr.(2)

Its easy to embrace science, especially in light of their history making changes when it was needed. They changed their name to Windsor from Saxe-Coburg and Gotha during World War I to help commoners forget the British royal family is German during a time that Germany was shooting at English men in Europe. Given that public relations success, they can certainly change their tune when it comes to science.

Perhaps due to an infusion of new blood outside the shockingly limited pool drawn from during the 19th and 20th centuries, Prince William seems to be a more genetically gifted thinker than his father. He can show it by embracing the modern world, where food and medicine are embraced.(3)

He doesnt actually have to divest from the farm, that is just me getting attention in a title. It is enough if he acknowledges that having peasants toil for his carrots only using specially labeled toxic pesticides is a pastime for the rich, and not a way to feed the world.

(1) The same way California Governor Gavin Newsom doesnt want people who make over $2 million each year to pay higher taxes to subsidize the electric cars the Governor insists Uber drivers need to buy. High taxes are for the middle class and the poor, not the donors he will need in order to fail running for President in 2024.

(2) Nothing looks more hypocritical than people on the left in England and the US suddenly endorsing vaccines when just two years ago they opposed them. It instead reeks of politics, and politics need to be a no-no for the new generation of British royals, lest they be relegated to the name recognition of the Queen of the Netherlands, whoever that is.

(3) and not just engage in publicity stunts about energy costs that are squarely the blame of the government his father now seeks to lead.

Hank Campbell founded Science 2.0 in 2006, and writes for USA Today, Wall Street Journal, CNN, and more. His first book,Science Left Behind,was the #1 bestseller on Amazon for environmental policy books. Follow Hank on Twitter@HankCampbell

A version of this article was originally posted atScience 2.0and is reposted here with permission. Science 2.0 can be found on Twitter@science2_0

See the original post here:
Viewpoint: Will King Charles abandon his kooky ideas about agriculture and help accelerate Britain's embrace of sustainable biotechnology tools? -...

Biotechnology is a fast-growing field that is revolutionizing healthcare and other industries. Biotech companies are developing new drugs, diagnostics, and agricultural products to meet the needs of society and global markets. Biotech stocks have also been performing well as of late. The market has been kind to biotech stocks over the past couple of years, and many analysts suggest that this trend will continue into 2022. So if youre looking for some great biotech stocks to buy in 2022, we can help you out. This article will discuss three top biotech stocks to buy in 2022 and provide helpful information about these companies and their competitors.

Aurinia is a pharmaceutical company focused on developing therapies for patients with rare and neglected diseases. The companys lead product, voclosporin, is designed to treat lupus nephritis, a kidney inflammation caused by systemic lupus erythematosus (lupus). The company has a robust business model, and voclosporin effectively treats lupus nephritis in several clinical trials. Aurinia is expected to begin Phase III clinical trials for voclosporin in early 2022. Aurinia Pharmaceuticals is currently trading at $4.56 per share. The company has a market cap of $1.03 billion and a price-to-book ratio of 1.44. The company is expected to have annual revenue of $784 million in 2022.

Verve is a pharmaceutical company focused on developing therapies for rare central nervous system (CNS) disorders and diseases of the eye. The companys lead product, a treatment for retinal vein occlusion (RVO), is currently in Phase III clinical trials. Verve was formed due to a merger between Neurocrine Biosciences and Ferrokinetics. After the two companies merged, the company was renamed Verve Therapeutics and continued to work on the same RVO treatment. Verves RVO treatment is expected to be commercially available in 2022. Verve Therapeutics is currently trading at $3.63 per share. The company has a market cap of $1.32 billion and a price-to-book ratio of 0.99. The company is expected to have annual revenue of $539 million in 2022.

Neurocrine is a biopharmaceutical company focused on developing therapies for severe and rare diseases. The companys lead product, INGREZZA, is destructive dyskinesia (TD), a movement disorder characterized by involute notary facial, arm, and leg movements. TD is a severe and long-term condition that is often associated with the use of certain psychiatric medications. INGREZZA is effective in treating TD in several clinical trials. Neurocrine was formed due to a merger between Vercure Pharmaceuticals and Ferrokinetics. After the two companies merged, the company was renamed Neurocrine Biosciences. Neurocrine Biosciences is currently trading at $26.37 per share. The company has a market cap of $5.37 billion and a price-to-book ratio of 1.69. The company is expected to have annual revenue of $1.13 billion in 2022.

Regenxbio is a biopharmaceutical company focused on developing immuno-oncology therapies and bispecific antibodies (Bi-SBIs). Immuno-oncology treatments are being developed to treat various cancers by activating the immune system. Bi-SBIs are engineered to bind to two different targets at the same time. The companys lead product, RG101, is being developed as a treatment for diabetic macular edema (DME), a degenerative eye disease that affects individuals with diabetes. RG101 is effective in treating DME in several clinical trials. In addition, the U.S. Food and Drug Administration (FDA) has also granted Breakthrough Therapy Designation designation. Regenxbio is currently trading at $27.09 per share. The company has a market cap of $2.39 billion and a price-to-book ratio of 4.24. The company is expected to have annual revenue of $1.32 billion in 2022.

Biotechnology is a fast-growing field that is revolutionizing healthcare and other industries. Biotech companies are developing new drugs, diagnostics, and agricultural products to meet the needs of society and global markets. Biotech stocks have also been performing well as of late. The market has been kind to biotech stocks over the past couple of years, and many analysts suggest that this trend will continue into 2022. If youre looking for some great biotech stocks to buy in 2022, we can help you out. This article will discuss three top biotech stocks to buy in 2022 and provide helpful information about these companies and their competitors. Now its time for you to decide which biotech stocks to buy in 2022. Remember that these are just some suggestions, so do your research before investing in any company or store.

Go here to see the original:
Top Biotechnology Stocks to Buy in 2022 - Best Stocks

There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and quality of life.

People often bequest money in their will to these organisations, donate after a loved one has been struck down by a particular illness or at funerals ask for donations to a an organisation in lieu of traditional flowers.

And while these organisations do great work, what about considering investing directly in medical companies for the greater good? Biotechnology investing is one sector which stands out for not only potential to deliver quality returns but also contribute positively to society.

Australias biotech representative body AusBiotech CEO Lorraine Chiroiu told Stockhead many of us unfortunately have a personal connection to catastrophic disease and, motivated by our experiences, are seeking avenues to put our philanthropic and investment dollars where we can make a meaningful and sustainable difference.

AusBiotech is receiving increasing enquiries from people who want to gift, bequeath or invest in a way that gives the best chance of new medical treatments and cures making their way to people experiencing disease, she said.

For example, we recently received a call from a father whose only son had passed away from cancer. Nobly, he wanted to make a purposeful investment into a company working to provide treatment for the disease that took his son in the hope that other families wouldnt have to go through the same suffering as his family.

Indeed many biotech companies have been founded by grieving family or friends that are passionate about finding a cure for a disease that took their loved one too soon.

Chiroiu said biotechnology companies are the vehicles that move medical research along the translation and commercialisation pathway to patients.

Companies operating in the life science and medtech sectors are in a unique position where business foundations are often influenced by a strong value-driven purpose one that offers positive social impact as the company develops life-saving and life-enhancing technologies.

Focusing clearly on patient impact, social good is codified into biotech companies DNA and are a great avenue for ethical investors to consider diversifying their portfolio.

She said we are living in an age of profound acceleration in medicinal discoveries and healthcare options, as well as a time that the Covid-19 pandemic has brought biotechnology especially in the form of vaccines into sharp focus.

As we emerge from the pandemic, the chronic health challenges and increasing burdens of disease associated with ageing populations around the world has many of us wondering how we can help move medical research from the bench to the bedside the answer is via business, she said

Australias biotech industry is on a strong growth trajectory, through substantially increasing numbers of organisations. Figures released by AusBiotech show the sector has grown 43% since 2019 and 60% since 2017.

Amid a thriving and expanding biotech industry in Australia, feeding the need for commercialisation, clinical development and growth is key and the diversity of investment sources remains a pressing issue, Chiroiu said.

Capital is the lifeblood of these companies and in response to this increasing need, AusBiotech has bolstered its investment program with a goal that Australian and overseas investors increasingly see Australian life sciences research and small-to-medium enterprises as viable and attractive investment options.

Global X head of investment strategy Blair Hannon told Stockhead biotechnology investing is well positioned to tick the boxes of environmental, social and governance (ESG) considerations of both institutional and retail investors.

For environmentally minded investors, the biotech industry has a low carbon footprint as most work is research-driven and not energy-intensive and as such, adding biotech exposure can help lower the average carbon footprint of a portfolio, Hannon said.

The biotech industry is highly regulated as measured by the S&P Biotechnology Select Industry Index and is free of any violators of the UN Global Compact (UNGC), which is a widely-followed benchmark of corporate good behaviour.

Hannon said alongside many other sectors, biotechs are striving towards ESG targets. Whilst a diversified biotech ETF such as its S&P Biotech ETF (ASX:CURE) is not explicitly tracking an ESG framework, Hannon noted many biotech companies within the fund focus on social good as their technology aims to aid people from all walks of life with disease treatments or even eradication.

Prescient Therapeutics (ASX:PTX)CEO and managing director Steven Yatomi-Clarke told Stockhead bringing life-changing therapies to patients is an incredibly challenging undertaking that requires resources and resilience.

PTX is at the forefront of game-changing personalised cancer treatments with a strong pipeline of promising therapies. The company has a growing list of collaborations with leading cancer organisations globally including Peter McCallum Cancer Centre, University of Texas MD Anderson Cancer Center, Yale, Oxford and UPenn.

Companies brave enough to take on this challenge call on investors to fund the research and development at least, until they become profitable, he said.

But at Prescient, when we accept a dollar from an investor, we are focussed on growing that into more than one dollar.

He said in the last two years, Prescient has spent around $8m of shareholder funds, but through consistent delivery of milestones and progress, the company has translated this $8m into over $100m of shareholder value.

So shareholders have enjoyed a handsome financial return, but additionally, they can be satisfied in knowing that their investment has resulted in incredibly exciting progress to create therapies that we believe are going to change lives.

AusBiotech is aiming to educate potential investors in life sciences companies about the unique ecosystem, through in-person events such as its AusBioInvest 2022 in Perth in October as well as plain English resources including The Guide to Life Sciences Investing

At Stockhead, we tell it like it is. While Prescient Therapeutics is a Stockhead advertiser, it did not sponsor this article.

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

It's free. Unsubscribe whenever you want.

You might be interested in

See the original post:
Biotechnology investing for the social good making money and a difference - Stockhead

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.

Nautilus co-founder and CEO Sujal Patel is scheduled to participate in the following two executive panel discussions:

Interested parties may contact kristen.patrick@capitalone.com to register to attend the virtual event.

About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit http://www.nautilus.bio.

Media Contactpress@nautilus.bio

Investor Contactinvestorrelations@nautilus.bio

Go here to read the rest:
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit - GlobeNewswire

NEW YORK What would you miss looking at the most if you lost your vision? According to a survey of 2,000 Americans, respondents say theyd miss seeing their childrens milestones (26%), scenes of nature (23%), their pets (22%), and their favorite TV shows and movies (15%).

When asked which of the five senses are the most important to them, vision tops the list with 77 percent of the votes. The other senses, such as hearing (14%), touching (6%), smelling (2%), and tasting (1%), trailed extremely far behind. With that in mind, its no surprise that 65 percent wish they took better care of their eyes, while another 58 percent feel they take their vision for granted.

Conducted by OnePoll for NVISION, the study also found that the average person first begins to worry about their vision at 39 years-old. Although 48 percent of respondents rate their eyesight as good, most find it easy to take care of their eyes (62%), because they care about their vision (69%), go to a good eye doctor (51%), and follow a daily routine (48%).

Meanwhile, a fifth find it difficult (19%), citing challenges like gaps in insurance coverage (48%), lack of resources (39%), and no way to access a good eye doctor (38%).

Regardless, 45 percent believe its very important to visit the eye doctor annually, with respondents saying theyve gone to their optometrist an average of four times in the last five years. Americans have also taken matters into their own hands with habits like eating a healthy diet (43%), wearing sunglasses (41%), getting more sleep (40%), drinking more water (40%), avoiding rubbing their eyes too much (39%), and washing their hands regularly (38%).

Every day, I see patients with eye diseases that were either preventable or treatable if caught earlier, says Dr. Dagny Zhu, a Harvard-trained surgeon at NVISION Eye Centers, in a statement. Patients who eat healthy, exercise regularly, dont smoke, and wear sunglasses can prolong the health of their eyes and delay the need for some treatments like cataract surgery. Other eye problems like glaucoma are silent and go unnoticed until its too late and significant vision has been lost. Thats why its so important to take care of your eyes and to see the eye doctor regularly for routine checkups.

The survey also asked respondents about their opinions on several eye health statements with 46 percent believing that staring directly at the sun is bad for your eyes, which Zhu says is the case. Many think wearing the wrong eyeglasses (39%) and staring at the TV very closely can cause damage (38%). Other statements people commonly believe are true include reading in dim light is harmful to your eyes (35%), using computers frequently can damage your eyes (35%), and you lose your vision as you age (34%).

Of the 72 percent of respondents whove never undergone LASIK surgery, 43 percent revealed they wouldnt be afraid to do so if their eyesight began to diminish. In comparison, 35 percent expressed hesitation, fearing permanent blindness (67%), pain (53%), and a lengthy recovery process (47%).

LASIK is one of the most studied elective procedures available today and has been shown to be safe and effective with a high level of patient satisfaction. LASIK is not painful, adds Zhu. There are many safety mechanisms built into the laser machine, making complications during the procedure extremely rare.

See original here:
Can you see me now? Average person begins worrying about their vision at age 39 - Study Finds

A rare, but serious, eye infection can be avoided in contact lens wearers who practice simple, healthy habits.

People who wear reusable contact lenses are nearly four times more likely to develop a rare, sight-threatening eye infection than those wearing daily disposables, a new study has found.

Multiple factors increase the risk of acanthamoeba keratitis (AK), including reusing lenses or wearing them overnight or in the shower, say the researchers from University College London.

READ MORE |6 top tips to keep your eyes healthy

AK is a condition that results in inflammation of the cornea. The rare but serious eye infection can result in permanent visual impairment or blindness, explains the US Centers for Disease Control and Prevention (CDC). While it is most common in people who wear contact lenses, anyone can develop the infection, it adds.

"Contact lenses are generally very safe but are associated with a small risk of microbial keratitis, most commonly caused by bacteria, and which is the only sight-threatening complication of their use," lead author, professor John Dart from the UCL Institute of Ophthalmology and Moorfields Eye Hospital NHS Foundation Trust, says in a university news release.

READ MORE | GRAPHIC: Woman has 14 worms pulled from eye after rare infection

Dart adds: Given that an estimated 300 million people across the globe wear contact lenses, it is important that people know how to minimise their risks for developing keratitis."

AK causes the front surface of the eye (cornea) to become painful and inflamed, explain the authors. The most severely affected typically end up with less than 25% of vision or become blind following the disease and face prolonged treatment. Overall, 25% of people affected require corneal transplants to treat the disease or restore sight.

What they found

The team recruited more than 200 patients from Moorfields Eye Hospital. Each patient was asked to complete a survey, including 83 people with AK. This was compared with a control group of 122 participants who came to eye care clinics with other conditions.

People who wore reusable soft contact lenses (such as monthly pairs) had 3.8 times the odds of developing AK compared to those who wore daily disposable lenses.

Heres what else they found:

READ MORE |Optometrist on good eye health

Previous studies have linked AK to wearing contact lenses in hot tubs, swimming pools or lakes, but the latest research adds showers to that list, and underlines that exposure to any water when wearing lenses should be avoided, says study author, associate professor Nicole Carnt.

Dart believes that all contact lens packaging should include basic information on lens safety, even a simple sticker warning stating 'no water' on each case.

That said, here are important safety tips for taking care of your contact lenses the right way.

"Basic contact lens hygiene measures can go a long way in avoiding infections, such as by thoroughly washing and drying your hands before putting in your lenses, says Dart.

See the rest here:
Contact lens wearers at higher risk of rare eye infection are you caring for your lenses the right way? - News24

Jeremy West (right) with Dr. Rahul Khurana (left), a retinal surgeon who operated on his eye.Slava Blazer Photography

A man almost lost his vision in one eye after opening a bottle of champagne on Mother's Day last year.

Jeremy West had an operation that saved his eyesight, but it never fully recovered.

People with champagne cork eye injuries should immediately go to the ER, a specialist told Insider.

A man almost lost his vision in one eye after a champagne cork flew into it during a Mother's Day celebration.

Ahead of Eye Injury Prevention Month in October, Jeremy West, 40, told Insider that the accident left him with worse vision and intermittent spots in his right eye "that look like a bug flying around."

Champagne cork eye injuries are rare, but when they occur the damage can be devastating and permanent, partly because corks can fly out of bottles at around 50 miles per hour, according to the American Academy of Ophthalmology (AAO).

West, a software engineer from the Bay Area in California, was dating a single mom at the time and decided to treat her to a Mother's Day brunch at his house, with mimosas.

That afternoon, on May 9 2021, West went to open a second bottle of champagne, placing it on a counter and standing behind it, using his thumb to release the cork. He expected it to fly out in front of him but it didn't.

"It happened very fast. All of a sudden, it went pop and then my eye was shut and I was in a ton of pain," hesaid.

West said that there was "extremely intense throbbing" in his right eye, "like you poked yourself in the eye, times a thousand."

When he tried to open it, he saw a yellow, orange color, caused by bleeding blood vessels.

"I could see bright spots where there were light sources, but I couldn't see my hand in front of my face," he said.

Due to its size, getting a champagne cork in the eye can be more dangerous than being punched, because it can pass bones to directly hit the eye, Dr. Rahul Khurana, West's surgeon and a clinical associate professor in ophthalmology at UCSF Medical Center, told Insider. The injury can cause the eye to bleed or rupture and the retina at the back of the eye to detach, leading to potential irreversible vision loss.

Story continues

It's "very important" to get seen immediately at the ER after getting hit in the eye with a cork, Khurana, who is also an AAO spokesperson, said. People should be monitored by an opthalmologist after the injury even if things seem OK at first, as problems can take a while to develop, he said.

After getting hit in the eye West immediately went to the ERin a taxi, where he passed out in the hot stuffy waiting room, in excruciating pain.

The ophthalmologist in the ER could only see blood in the eye at the time, so they gave West eye drops and advised him to sit upright to help clear it. After West was discharged, his eye was assessed twice a week for the next few weeks.

As it was healing, West noticed a black shadowy patch at the bottom right of his vision, and sometimes he'd get "these weird, like bright halo effects" around the outside of his eye.

It got so bad that he couldn't see out of the bottom third of his eye, and he lost his peripheral vision.

The ophthalmologist referred West to Khurana, who diagnosed him with retinal detachment. West had urgent surgery, where a silicon band was placed around his eyeball to try to squeeze the retina back into place.

The bruising and swelling from surgery took two weeks to settle. West also needed a vitrectomy, which removed the gel-like substance from the middle of the eye and meant he had to sleep upright for two weeks, as well as a "painful," "hot" laser treatment.

It took four months for his eye to heal and his vision has never fully recovered.

Khurana recommended that people follow the AAO's guidance to prevent champagne cork injuries, such as chilling the champagne before opening, placing a towel over the cork when opening, and pressing down as you twist the bottle open.

West gets anxious when others open champagne around him,but he continues to drink mimosas, always using a towel to open the bottle.

"Sometimes when I open a bottle, I get a little jumpy," he said.

Read the original article on Insider

More here:
A man who popped a champagne cork into his eye says it felt like being poked 'times a thousand.' His vision was saved after months of treatment but it...

HOUSTON, Sept. 26, 2022 /PRNewswire/ --Whitsett Vision Group announced today it is the first ophthalmologist group in the country to perform cataract surgeries using a new lens approved by the Food and Drug Administration (FDA) and that the practice has added another lens to its patient offerings. Both lenses have been shown to improve patients' vision and overall quality of life.

The two new lenses include the Lenstec ClearView 3, a multifocal intraocular lens, and the RxSight Light Adjustable Lens (LAL).

"Through recent advancements and technology, we can correct cataracts and enhance our patients' quality of life as we've never been able to before," said Jeffery Whitsett, board-certified ophthalmologist, and founder of the Whitsett Vision Group and VISTA Ophthalmics.

In clinical trials, patients reported having high-quality distance and near vision after receiving the ClearView 3 lens. They also did not experience dysphotopia, a common condition after cataract surgery, which is best described as the appearance of arcs, streaks, starbursts, or rings.

"The ClearView 3 from Lenstec has been designed with increased precision, accuracy, and stability, which results in excellent long-term visual outcomes at near, intermediate, and distance," said Whitsett.

Whitsett and his team performed the first surgeries using ClearView 3 as recently as Aug. 15.

The LAL lens is another option for Whitsett Vision Group's patients and is the only intraocular lens that enables ophthalmologists to customize a patient's vision after cataract surgery.

"This lens allows us to customize vision for each patient and adjust after surgery during a routine appointment. It can be adjusted to meet every patient's lifestyle needs and allows them to essentially 'test drive' the lens to experience and design their best visual outcome with complete confidence," said Whitsett.

Studies show that patients receiving the LAL and the recommended post-surgery treatments were more likely to achieve 20/20 vision or better without glasses than cataract patients with standard lens implants.

Surgeries using the LAL lens at Whitsett Vision Group started in late August.

Whitsett, who has helped pioneer ophthalmology research for new devices, procedures, and medications, was heavily involved in the FDA trials for the ClearView 3.

For more information about Whitsett Vision Group, visitwww.whitsettvision.com.

Images, videos, and background images are available here.

About Whitsett Vision Group

Whitsett Vision Group was founded in 1999 by Dr. Jeffrey Whitsett to bring superior eye care and surgical vision treatment options to the city of Houston. Since its inception, Whitsett Vision Group has been focused on custom cataract and LASIK surgery, utilizing advanced technologies and innovative lens solutions to provide patients with the best visual outcomes after surgery. More information about Whitsett Vision Group is available atwww.whitsettvision.com.

Media Contact:

Laura Frnka-DavisLFD Communications for Whitsett Vision Group713-409-1480[emailprotected]

SOURCE Whitsett Vision Group

See the rest here:
Whitsett Vision Group First to Use Revolutionary New Lens to Dramatically Improve Patients' Eyesight - PR Newswire

Highlights

Mr Grillet has developed a condition known as retinal detachment in his right eye and, as a result, has lost more than 50 per cent of his sight.

Oswaldo Grillet finds peace and the ability to switch off his daily concerns while practising yoga.

Normally, an operation can resolve the (retinal detachment) if treated immediately, but I was in a remote location and it took two or three days before I was able to see a real professional, he recalls.

... in life there is always a before and an after... you must learn to let go when you have to let go...

Mr Grillet says he was mountain bike riding in a remote part of New Zealand when he noticed a problem in his vision which literally stopped him in his tracks and forced him to seek urgent medical attention.

Oswaldo Grillet used to enjoy mountain bike riding.

Without a doubt, in my life there is a before and after... and you have to learn to let go... and yes, I had to stop doing things I loved, or I had to do them differently and make adjustments," he said.

A new beginning

With the partial loss of his vision, he says he was forced to look for paths that allowed him to practice introspection and in that space, he says discovered his priorities and the ways to accept the changing processes in life.

... whenever you lose something, a new space is created... it's an opportunity to understand that something new and different is coming.

Discovering a 'scientific, mystical path'

Mr Grillet is an experienced practitioner of yoga and meditation who began exploring both techniques in Venezuela when he was a teenager, and, years later, he travelled to India where he lived as a monk, studying and practising yoga, devotional music, transcendental meditation and Ayurvedic medicine.

This wealth of knowledge facilitated his path after his diagnosis, and increased his personal awareness to help him find ways to adapt to the new circumstances.

You think you're being productive the more active you are but it turns out that you might be hurting yourself because your stress levels are too high, even if you're doing a sport.

Knowing how to meditate helps you perceive life as it is and not as your mental conditioning wants it to be... that's what's important... and if you think about it and decide to consider making it part of your life, you're going to empower yourself, you're going to be at peace, regardless of what is happening in the external world.

The International Day of Yoga

During the pandemic, there was a growing tendency for people around the world to adopt this practice to stay healthy and rejuvenated and to combat social isolation and depression, says the UN.

... yoga also played an important role in the psychosocial care and rehabilitation of patients with COVID-19 to alleviate their fears and anxieties.

See original here:
'As one door closes, another opens': Adelaide man turned to yoga, meditation after major vision loss - SBS

Stephen Curry is undoubtedly the greatest shooter of all time but he suffers from a genetic eye disease with no known cure.

When we say Stephen Curry is one of a kind, we mean it. Every other player in the league current or past has a parallel.

Take Shaquille ONeal for example. The 71 center was perhaps one of the most dominant players ever. Yet, he himself believes Giannis Antetokounmpo is a close comparison to him in the modern-day game.

But when it comes to Curry, there is no alternative to him. No one can shoot as consistently as him or run through screens all day, or drive to the ring the way he does. Its the complete package of Stephen Curry that overwhelms opponents.

Contrary to what fans would believe, though his lethal from beyond the arc, three-point shooting is not the pillar of his game. It is in fact his ability to use any aspect of his game on any given night.

Three-pointers not landing? Curry just drives to the rim. Getting bodied by bigger players? He stays in constant motion to beat defenders.

On top of his scoring abilities, Steph is an exceptional court general. His playmaking is second to none. The vision to find open shooters or thread the needle through busy lanes, make the Chef one of the most valuable assets in league history.

But unfortunately, there is a high probability Stephen Curry may lose his eyesight.

Also read: Michael Jordan, who reportedly wants to sell $1.57 Billion Charlotte Hornets, entrusts his right-hand man with new contract

Its ironic that Stephen Curry, the greatest shooter of all time, suffers from an untreatable eye condition. In Keratoconus, a chronic disease that cannot be treated, the cornea bulges outwards like a cone.

This impacts how light is perceived by the eye causing blurred vision and incapability to read or drive.

Curry found out about the disease in 2019 after a shooting slump. Curry addressed the poor performance by getting contact lenses.

Though the lenses have helped the 4-time NBA Champ see the board clearly, it does not automatically make his eyes better.

The issue with Keratoconus is that it never goes away. Stephs natural vision will always remain blurred. In fact, Keratoconus progressively gets worse as time passes by.

Also read: In 7-years LeBron James will be eligible for pension and not get it: Kendrick Perkins gives his list of top 5 players

The rest is here:
Stephen Curry, whose $185,000 worth vehicle almost took his life, is sure to lose his eyesight due to a genetic defect - The Sportsrush

Donny W. Suh, MD, FAAP, MBA, FACS, Chief of Pediatric Ophthalmology and Strabismus, and Professor, Department of Ophthalmology and Visual Science, Gavin Herbert Eye Institute, University of California, Irvine, named recipient of the 8th Annual Bonnie Strickland Champion for Children's Vision Award from the National Center for Children's Vision and Eye Health at Prevent Blindness.

CHICAGO, Sep. 27, 2022 /PRNewswire-PRWeb/ -- The National Center for Children's Vision and Eye Health at Prevent Blindness (NCCVEH) has announced the recipient of the eighth annual "Bonnie Strickland Champion for Children's Vision Award" as Donny W. Suh, MD, FAAP, MBA, FACS, Chief of Pediatric Ophthalmology and Strabismus, and Professor, Department of Ophthalmology and Visual Science, Gavin Herbert Eye Institute, University of California, Irvine. The award will be formally presented at the NCCVEH Annual Meeting, to be held virtually, on Friday, Oct. 14, 2022.

The Bonnie Strickland Champion for Children's Vision Award recognizes significant efforts by an individual or group of individuals to improve public health approaches for children's vision and eye health at the state or national level. The award was established in 2014 by the Advisory Committee of the National Center for Children's Vision and Eye Health at Prevent Blindness to honor Bonnie Strickland and her groundbreaking work to establish a comprehensive system for children's vision in the U.S. She served as Director of the Division of Services for Children with Special Health Needs, Maternal and Child Health Bureau, before her retirement in 2014.

Dr. Suh has been named as the 2022 Bonnie Strickland Champion for Children's Vision Award recipient in recognition of his unique approach to connecting vision to overall health by aligning pediatrics and eye care; reducing barriers to eye care and improving vision health equity; and his participation in critical research that advances understanding of children's vision and eye health as well as vision disorders. Dr. Suh conducted research on school attendance and performance for children screened through the UC Irvine Mobile Eye Clinic, which will enhance the field's understanding of the connection of vision to academic success.

Dr. Suh currently serves as medical director of the UC Irvine Mobile Eye Clinic. The van began making school visits seven years ago and has provided vision screening for more than 20,000 preschoolers in Orange County, Calif. Since his appointment at UC Irvine, Dr. Suh, has increased fundraising efforts and success for this community outreach, as he did with a similar pediatric vision van program at his former institution, the University of Nebraska Medical Center, where more than 3,500 children were evaluated and treated each year.

Dr. Suh is also being recognized for his important work in training pediatric ophthalmologists and his leadership within the American Academy of Pediatrics for improving communications between the fields of pediatrics and ophthalmology, and developing vision screening guidelines.

"I am truly honored and humbled to be recognized by the NCCVEH as the Bonnie Strickland Champion for Children's Vision Award. Bonnie is an inspirational figure and a true champion advocating for our children's vision. Vision Screening programs have been a team effort from the public health sector, educators, school nurses, and community stakeholders, to make our dreams come true with a single vision," said Dr. Suh. "Also, there have been many people before me who dedicated tremendous sacrifices to make these programs possible. I would like to share this award with my Pediatric Eye Mobile team and the predecessors who made it possible. As Henry Ford once said, 'Coming together is the beginning. Keeping together is progress, and working together is success!'"

"Prevent Blindness has declared 2022 as 'The Year of Children's Vision," and we thank Dr. Donny Suh for his exemplary efforts and decades-long dedication to providing children with the access to quality eyecare services they deserve," said Jeff Todd, president and CEO if Prevent Blindness. "We enthusiastically congratulate Dr. Suh for being named the recipient of this year's Bonnie Strickland Champion for Children's Vision Award and look forward to working with him to continue his sight-saving efforts!"

Past recipients of the Bonnie Strickland Champion for Children's Vision Award include Shavette L. Turner, vice president, Children's Vision Services at Prevent Blindness Georgia; Logan Newman, founder of the East High School Vision Care Program; Anne L. Coleman, MD, MPH, UCLA Stein Eye Institute; the Vision in Preschoolers (VIP) Study Group; Richard Bunner, retired from the Ohio Department of Health; Sean P. Donahue, MD, PhD, Professor of Ophthalmology and Visual Sciences at Vanderbilt University; the Illinois Eye Institute (IEI) at Princeton Vision Clinic; and the Pediatric Physicians' Organization at Children's. For more information on the 2022 Bonnie Strickland Champion for Children's Vision Award, Prevent Blindness or the NCCVEH, please visit nationalcenter.preventblindness.org or contact Donna Fishman at dfishman@preventblindness.org.

About the National Center for Children's Vision and Eye Health at Prevent Blindness Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. In 2009, Prevent Blindness established the National Center for Children's Vision and Eye Health, with funding and leadership support from the HRSA- Maternal and Child Health Bureau. Serving as a major resource for the establishment of a public health infrastructure, the National Center advances and promotes children's vision and eye care, providing leadership and training to public entities throughout the United States. The National Center is advised by a committee of national experts and leaders from the fields of ophthalmology, optometry, pediatrics, nursing, family advocates and public health to guide the work and recommendations of the Center. For more information, or to make a contribution to the sight-saving fund, call (800) 331-2020, or visit us at https://nationalcenter.preventblindness.org/.

###

Media Contact

Sarah Hecker, Prevent Blindness, 312.363.6035, shecker@preventblindness.org

Twitter

SOURCE NCCVEH

See the original post:
NCCVEH Names Dr. Donny W. Suh, Gavin Herbert Eye Institute, UC Irvine, as Recipient of the 8th Annual Bonnie Strickland Champion for Children's Vision...

We have a game-changing offering for how people access and experience employee benefits - with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible and affordable health benefits.

SAN CARLOS, Calif. (PRWEB) September 28, 2022

XP Health, the company creating the first digital-first vision benefits platform, today announces a $17.1M Series A round led by HC9 Ventures, Valor Capital Group and ManchesterStory. Additional investors include Canvas Ventures, CameronVC, Core Innovation Capital, GSR Ventures, and Plug and Play, as well as high profile angels like Ken Goulet (former EVP Anthem), Kevin Hill (former regional CEO United Healthcare), Jeff Epstein (CFO of Oracle, partner at Bessemer Venture Partners) and Brett Rochkind (former managing partner General Atlantic). This expansion capital will bolster XP Healths drive to reinvent how people experience vision benefits.

XP Health offers a high-quality, innovative vision care benefit that doubles the value of coverage while reducing costs by half for members. This recent fundraise follows a successful 2021 for the company, during which it raised $5.5 million and was named one of Fast Companys Most Innovative Companies. Starting with just 30 clients last year, XP Health now services 1,500, including high-profile companies like Docusign, Chegg, Navistar, Sequoia Consulting, and strategic partners Guardian Life Insurance and The Health Benefit Alliance. All-in, XP Health covers more than 250,000 people.

Through its integrated supply chain, XP Health keeps costs low by removing the middlemen that add significant markups at several steps in the process. This business model has helped triple vision benefits coverage for employees while reducing their out-of-pocket costs by 80 percent, all while cutting employer eyewear claim costs by 40 percent. This model has also helped the company to grow their revenue by 9,300 percent since January 2021.

This round of funding enables us to strengthen the platforms functionality and provide a stellar consumer experience in the most affordable way to employers, insurance carriers, and employees, said Antonio Moraes, Co-Founder, and CEO of XP Health and a former impact venture capital investor. We have a game-changing offering for how people access and experience employee benefits - with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible, and affordable health benefits.

Vision coverage has remained static, complicated, expensive, and unsatisfying for decades. An estimated 93 million adults in the United States (about 25 percent of the population) are at high risk for serious vision loss, but only half visited an eye doctor in the past 12 months [1]. XP Health uses advanced technology to transform vision care into something people - whether they have 20/20 eyesight or need a prescription - are excited to use, and has a unique business model that lowers costs for all parties.

The XP Health team is bringing some much-needed change to vision benefits. HC9 is excited to leverage our experience and network to help XP Health accelerate growth while improving eye health, said Jon Gordon, General Partner of HC9 Ventures. We know firsthand what it is like to operate and grow businesses that are driving health innovation, and XP Health is the perfect partner.

We believe that XP Health will fundamentally transform the future of vision benefits and are thrilled to contribute to their mission to innovate in the space, said Michael Nicklas of Valor Capital Group. XP Health is working hard towards expanding access to high quality vision care to millions of employees in the United States and we are proud to have backed the company since day one.

As an insuretech-focused investor, we know that quality benefit programs make a big difference in a companys ability to attract and retain employees, which is especially important given the current state of the job market, said David Miles of ManchesterStory. XP Health is on a path to make vision care a 'must have' core employee benefit. Our confidence in XP Healths founding team and their passion for the end-consumer made XP Health an investment opportunity we could not pass up.

About XP HealthXP Health democratizes access to high-quality, delightful experiences in vision care that double coverage and reduce costs by half. It is the first modern vision platform focused on eye care and eyewear that can be used to enhance or replace existing vision plans, and uses artificial intelligence, augmented reality, and customer-centric design to create a stellar member experience. XP Health was named to the 2021 Fast Company list of the Worlds Most Innovative Companies and over the past year has expanded from 30 to 1500+ customers, including Docusign, Palantir, Chegg, Sequoia Consulting, and strategic partner Guardian Life Insurance. To learn more visit xphealth.co.

About HC9HC9 is an early-stage venture capital firm purpose-built to provide industry-specific expertise to emerging healthcare software and services companies. HC9s unparalleled, deeply-engaged investor community of leading executives, entrepreneurs, and investors collectively has thousands of years of experience in all facets of healthcare. We leverage the power of that experience to support the founders that are shaping the future of healthcare. For more information, please visit http://www.hc9.vc.

About Valor Capital GroupValor Capital Group is a global venture capital firm, focused on early-stage and growth equity investments. Currently, the Group has over $2 billion AUM, distributed across six funds. Valor pursues a cross-border strategy with a focus primarily in Brazil and throughout Latin America, as well as investing in international companies and helping them expand into the region. Since inception, the Firm has invested in over 100 companies, 20 of which are unicorns.

About ManchesterStoryManchesterStory partners with world-class founders pursuing technological innovation in InsurTech and adjacent sectors. Focused on early-stage start-ups, ManchesterStory leads venture capital investments to fund growth while also connecting them with leading financial services companies across North America and beyond.

[1] https://www.cdc.gov/visionhealth/resources/publications/high-risk-vision-loss.html#:~:text=In%202017%2C%20approximately%2093%20million,exam%20in%20the%20last%20year.

Share article on social media or email:

More:
XP Health Raises $17.1M Series A to Transform Vision Benefits for Insurance Carriers, Companies and Employees - PR Web

four a day 28/09/2022 9:02 pm

ocular herpes

Ringworm is a rash that appears as small blisters on the skinusually on the torso, although it can also appear on the abdomen, legs or face, and is caused by reactivation of the chickenpox virus. smallpox virus as if sleeping in our body, but After years it reactivates and herpes zoster infection appears.,

One of the existing types of herpes zoster is ophthalmic:

Redness of the eye.

Foreign body sensation.

Constant tearing.

{{ #leaves }}

{{#section.link.href}} {{section.link.title}} {{/section.link.href}}

{{ /leaves }}

-Photophobia or sensitivity to light.

-Low vision if shingles affects the retinal area.

Rash or swelling on the eyelids.

If the herpes reaches the cornea, then the scars can be seen

If the disease is not treated May continue to progress manifesting as corneal ulcers, In more advanced stages, the herpes virus can seriously damage the cornea, even perforating it. It usually affects only one eye.

Once a diagnosis is made by an ophthalmologist, treatment will aim to treat the symptoms and prevent new episodes. For this, Adequate eye hygiene with physiological serum will be done daily and antiviral and anti-inflammatory drugs will be prescribed,

In extreme cases, if ocular herpes has caused significant loss of vision due to damage to the cornea, a corneal transplant may be a solution.

Systemic treatment of herpes zoster shortens the healing process, preventing or relieving pain and other complications Acute or chronic, especially when administered within the first 72 hours of symptoms.

The most frequent complications of herpes zoster ophthalmicus are those affecting the eyelid skin (blepharitis) and/or the conjunctiva (conjunctivitis). Involvement of the cornea (keratitis) is most severe and can leave sequelae affecting vision. other thing, Intrauterine inflammation can produce sequelae such as cataracts or glaucoma and inflammation of the retina (retinitis) Can skip important sequences,

Although this type of shingles can have different results., Carmen suffered from this ringworm: It affected my eyesight and I lost a lot of vision. Now I have monocular vision and my eyes are very tired, he explained. I would tell people suffering from this to go to the doctor immediately because you can prevent the nerve from being affected as it happened to me.

The average duration of shingles is 2 to 4 weeks, It can be reduced if treatment is applied with the first symptoms. For this reason, it is very important to go to the doctor as soon as the pain starts or as soon as the first blisters appear.

Herpes zoster has a low mortality rate, but its complications, especially postherpetic neuralgia, can cause disability and affect the quality of life of people suffering from it, There is no cure for this disease, but it is preventable. For more information consult your doctor and visit the website http://www.virusherpeszoster.com.

See original here:
Everything You Need To Know About Ocular Herpes Zoster: Symptoms, Treatment, And Complications - World Nation News

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

Read this article:
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell...